• ChemFaces is a professional high-purity natural products manufacturer.
  • Product Intended Use
  • 1. Reference standards
  • 2. Pharmacological research
  • 3. Inhibitors
  • Home
  • Natural Products
  • Bioactive
  • Screening Libraries
  • Hot Products
  • Plant Catalog
  • Customer Support
  • Product Use Citation
  • About Us
  • Contact Us
  • Bioactive Products
    Catalog No. Information
    CFN99995 2,3,5,4'-Tetrahydroxyl diphenylethylene-2-O-glucoside

    1. 2,3,5,4'-Tetrahydroxyldiphenylethylene-2-O-glucoside(TSG) blocks the proliferation of PASMCs induced by PDGF-BB through arresting the cell cycle in G0 / G1 phase, indicates that TSG suppress PDGF-BB-induced PASMCs proliferation is associated with an inhibition of AKT / GSK3β signaling pathways.
    2. TSG not only prevents over-expression of α-synuclein at an early stage, but also reverses the increased expression of α-synuclein and inhibits the aggregation at the late stage of Tg mice, it may have potential to the prevention and treatment of Alzheimer's diseases.
    3. TGS, emodin and physcion have the lipid regulation activity to an overall synergy.
    CFN98411 Medicarpin

    1. Medicarpin, a legume phytoalexin, acts as an estrogen receptor (ER) agonist, can stimulate osteoblast differentiation likely via ERβ, promote achievement of peak bone mass, and is devoid of uterine estrogenicity; in addition, given its excellent oral bioavailability, it can be potential osteogenic agent.
    2. Medicarpin exhibits no uterine estrogenicity, however it can inhibit osteoclastogenesis and has nonestrogenic bone conserving effect in ovariectomized mice.
    3. Medicarpin and maackiain and two of their biosynthetic precursors inhibit the constitutive and phenobarbital (PB)-induced types of AHH, but have little effect on the 3-methylcholanthrene (MC)-induced type of AHH.
    4. Medicarpin sensitizes myeloid leukemia cells to TRAIL-induced apoptosis through the induction of DR5 and activation of the ROS-JNK-CHOP pathway.
    5. Medicarpin has antifungal activity.
    CFN98526 Anhydroicaritin

    1. Anhydroicaritin can improve diet-induced obesity and hyperlipidemia and alleviate insulin resistance by suppressing SREBPs activation, it can serve as a leading compound for pharmacological control of metabolic diseases.
    2. Anhydroicaritin has the potential of stimulating the formation of mineralization nodules and further speeding up the formation of bone, indicates that it may be a potential candidate for bone regenerative medicine.
    3. Anhydroicaritin has strong activity in scavenging DPPH radical ,and effective inhibition against lipid peroxidation.
    4. Anhydroicaritin possesses significant protective effects on the zymosan-induced peritonitis mice, which may be associated with the regulation ofCa2+, influx in macrophages and iNOS expression.
    5. Anhydroicaritin exhibits immunosuppressive effect on the mouse macrophages stimulated by LPS, it is promising to be developed as an immunosuppressive reagent.
    CFN00020 Taurine

    1. Taurine, a free β-amino acid with remarkable antioxidant activity, is used in Taurine-enriched beverages to boost the muscular power of athletes.
    2. Taurine can attenuate nandrolone decanoate-induced poor sperm quality and testicular toxicity in rats.
    3. Taurine can effectively promote chondrocyte growth and enhance accumulation of glycosaminoglycans and collagens in the conditioned media of chondrocytes, it is effective in proliferation promotion and phenotype maintenance of chondrocytes, thus, taurine may be a useful pro-chondrogenic agent for autologous chondrocyte implantation in the treatment of cartilage repair.
    CFN98894 Apigenin 7-O-methylglucuronide

    1. Apigenin 7-O-methylglucuronide did not affect GAG level or secretion, may potentially be used in osteogenesis imperfecta (OI) type I pharmacotherapy in patients with normal GAG content.
    2. Apigenin 7-O-methylglucuronide which normalized collagen synthesis in OI cells may exert their effects through beta1-integrin-mediated signaling.